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Herpesvirus reactivation is common after liver transplantation.
Objective: Analyze the presence of cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-
6)  DNA in liver donor biopsies, seeking to better understand issues involving human donor
leukocyte antigens (HLA)-A, B and DR, as well as correlations with acute cellular rejection.
Methods: Fifty-nine liver transplantation patients were investigated for the presence of
HCMV and HHV-6 DNA in liver donor biopsies, using the Nested-PCR technique. The clinical
donor information and HLA matches were obtained from the São Paulo State Transplant
System. The recipients’ records regarding acute cellular rejection were studied.
Results: Seven (11.8%) biopsies were positive for HCMV DNA and 29 (49%) were positive for
HHV-6 DNA. In 14 donors with HLA-DR 15 nine had HHV-6 DNA positive liver biopsy with a
tendency for significant association (p = 0.09), 22 recipients developed acute cellular rejection
and 9/22 were positive for HLA-DR 15 (p = 0.03; 2 = 4.51), which was statistically significant
in  univariate analysis and showed a tendency after multivariate analysis (p = 0.08).Conclusion: HHV-6 DNA was prevalent in liver donors studied as well as HLA-DR 15. These
findings suggest that patients with HLA-DR 15 in liver donor biopsies develop more  rejection
after liver transplantation.
in 14–82% of solid organ transplantations. HCMV infection
In liver transplantation patients, cytomegalovirus (HCMV) and
human herpesvirus-6 HHV-6 are the most common infec-
tions. These viruses undergo latency and reactivation episodes
in the host. HCMV prevalence ranges from 20% to 60%.
Among patients with active infections, 80% develop clinical
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may vary depending on baseline HCMV-specific immunity
(donor and recipient seropositivity), the overall net state
of immunosuppression. HCMV infection may be the result
eserved.
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f reactivation or reinfection (in HCMV-seropositive recipi-
nts) or primary infection (in a HCMV-seronegative recipient
ho  received an allograft from a HCMV-seropositive donor
D+/R−]).3
The role of human leukocyte antigen (HLA) between donor
nd recipient in organ transplantation has been widely stud-
ed and some authors suggest that HLA-A, B, or DR mismatch
ncreases the incidence of HCMV hepatitis in both primary and
econdary HCMV infections and is associated with increased
raft failure. HHV-6 reactivation and infections after liver
ransplantation are asymptomatic, although the risk factors
re not completely defined.4–6
The aim of the present study was to analyze the presence
f HCMV and HHV-6 DNA in liver donor biopsies, seeking to
etter understand issues involving HLA-A, B, and DR donor, as
ell as associations with acute cellular rejection.
At the Clinical Hospital of the Sao Paulo State University in
ampinas – Unicamp – in the period between January 2006 and
ecember 2008, 59 orthotopic liver transplants were carried
ut at the Liver Transplant Unit. The patients were followed
p and their donor liver biopsies were used in this study.
The liver biopsies were collected from the organ before
ransplantation at the bench (pre-transplant graft biopsy).
his was an observational, analytic, longitudinal prospective
ohort study.
Children and retransplantation patients were excluded
rom the study. A total of 59 patients enrolled met  the follow-
ng inclusion criteria: 1 – sufficient liver biopsy material for
NA virus analysis by the N-PCR method; 2 – clinical donors’
nformation available from the State Transplant System, São
aulo, Brazil.
The presence of HCMV and HHV-6 DNA N-PCR was inves-
igated as well as their co-infection in liver donor biopsies.
hese analyses were performed in formalin-fixed paraffin-
mbedded material. Patients’ records were analyzed in the
rst six months post-transplant period to assess acute cellu-
ar rejection. HLA matches were obtained from the Sao Paulo
ransplant system.
All patients from this study had received prophylaxis for
erpes simplex infection and standard immunosuppressive
herapy according to our protocol.7 All recipients had positive
gG for HCMV before transplantation and there was no recipi-
nt serology for HHV-6 before transplantation. All donors had
ositive serology for HCMV and no HHV-6 serology results.
Diagnosis and monitoring of graft acute cellular rejec-
ion were performed according to the Banff International
onsensus.8 All acute rejection episodes were treated with
ethilprednisolone according to our protocol.
Viral DNA was extracted from liver biopsy specimens using
he Qiagen Dneasy tissue kit (Uniscience, São Paulo, Brazil)
ccording to the manufacturer’s instructions with some mod-
fications to achieve final elution volumes of 30 L.7
Five microliters of extracted DNA were used for the N-
CR for HCMV and HHV-6 using a mixture containing specific
rimers (HCMV primers; Invitrogen, São Paulo, Brazil), using
 previously described technique9 with some modifications.
pecific primers for HHV-6 (HHV-6 primers; Invitrogen) were
pplied with a technique previously described by Secchiero
t al.10 with some modifications. The amplifications were per-
ormed in a Peltier Thermal Cycler (MJ  Research, Waltham,4;1 8(2):220–224 221
MA,  USA). The N-PCR products were analyzed under UV light
after electrophoresis in agarose gel (Gibco-BRL Life Technol-
ogy, Carlsbad, CA, USA) in tetramethylbenzidine buffer after
staining with ethidium bromide. All primer sequences and
PCR products were analyzed using the Genbank database
before initiating the study. PCR using primers for beta-globin
gene amplification, which were performed on samples to
detect possible false-negative results, were not included in this
study.7
Categorical variables were compared using Fisher’s exact
test and multiple regression analysis was performed using
acute cellular rejection as the dependent variable by Statsoft
11.0 program (NY, USA, 2012). p < 0.05 was considered statisti-
cally significant.
This study was approved by the Institutional Ethics Com-
mittee of the Faculty of Medical Sciences, UNICAMP (CEP no.
030/2006).
Fifty-nine liver donors were studied, 36 (61%) were men  and
23 (39%) were women.
Thirty (51%) donors were of blood group O, 22 (37%) blood
group A, five blood group B, and two group AB. The mean
age was 32.2 years ± 13.0. Thirty-one (52%) donors died due to
traumatic brain injury, 21 (35%) donors due to cerebrovascular
accident (CVA) and seven donors had other causes of death.
Twenty-nine (49%) out of 59 donors studied had a positive
serology for HHV-6 DNA and seven (11.8%) were for HCMV-
DNA. Liver donor biopsies had a co-infection (HCMV and HHV-
6) positivity rate of 10% (6/59).
We also investigated HLA matches (A, B and DR locus)
between HCMV-DNA and HHV-6-DNA. These data are
described in Table 1. Of the 14 (23.7%) donors with HLA-DR15,
nine (64%) were positive for HHV-6 DNA at liver biopsy with
a tendency for significant association (p = 0.09; Fisher’s exact
test). No association was found between CMV  DNA positivity
in liver biopsies and HLA-DR 15.
After liver transplantation, 22 (37%) recipients developed
acute cellular rejection and 41% (9/22) had HLA-DR15 (p = 0.03;
2 = 4.51; Fisher’s exact test). Moreover, in multivariate anal-
ysis presence of DR15 had a tendency to be associated with
acute cellular rejection after transplantation (Table 2). Like-
wise, HLA DR15 was associated with HHV-6 positivity in donor
biopsies.
The results of the present study indicate that HHV-6 DNA
and HCMV DNA were commonly detected in donor liver trans-
plantation at the Liver Transplant Unit – Unicamp, as shown
in other studies we have previously carried out.11 HHV-6 and
HCMV in patients are common after liver transplantation and
the interaction of these viruses can increase their pathogenic
effects.12–14
In our study, HHV-6 DNA was observed in 49% and HCMV
DNA in 11.8% of donor liver biopsies. We could find no pub-
lished reports to confirm these data but it is known that these
viruses can have an incidence of over 80% (serologic status) in
the human population.15,16 This is an important fact because
herpesviruses can establish a latent infection for the lifetime
of the host.17 A recent study identified high intrahepatic HHV-
6 viral load, suggesting that HHV-6 reactivation in the liver
18graft is of clinical relevance.
In our results, of 23.7% (14/59) HLA-DR15 donors, nine 9
(64%) had positive HHV-6 DNA at liver biopsy with a tendency
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Table 1 – Donor HLA information association with HHV-6 and CMV  DNA and acute cellular rejection in
post-transplantation period.
Donor case HLA Donor liver biopsies Post-tranplantation
A B DR HHV-6 DNA HCMV DNA ACR
1 2, 11 7, 27 1, 15 Positive Positive Positive
2 1, 2 8, 15 3, 15 Positive Negative Positive
3 26, 66 38, 5 11, 15 Negative Negative Positive
4 11, 23 44, 57 11, 15 Negative Negative Positive
5 2, 24 7, 57 7, 15 Positive Positive Positive
6 2, 3 42, 44 7, 15 Positive Negative Positive
7 24, 30 18, 35 11, 15 Positive Negative Positive
8 0, 2 40, 50 7, 15 Positive Negative Positive
9 24, 29 7, 44 7, 15 Negative Negative Positive
10 2, 11 35, 44 12, 14 Positive Negative Positive
11 31, 32 0, 4 4, 11 Positive Negative Positive
12 2, 26 15, 46 4, 13 Negative Negative Positive
13 1, 68 78, 55 1, 13 Negative Negative Positive
14 2, 32 39, 51 1, 4 Negative Negative Positive
15 0, 2 5, 9 4, 6 Negative Negative Positive
16 0, 8 2, 4 8, 1 Negative Negative Positive
17 2, 0 44, 39 11, 16 Negative Negative Positive
18 69, 35 0, 0 0, 0 Positive Negative Positive
19 3, 32 35, 0 8, 13 Negative Negative Positive
20 3, 0 15, 40 8, 11 Positive Negative Positive
21 2, 68 40, 57 4, 7 Negative Negative Positive
22 3, 11 35, 51 3, 11 Positive Negative Positive
23 3, 32 15, 35 1, 11 Positive Negative Negative
24 24, 32 35, 44 11, 15 Negative Negative Negative
25 3, 24 35, 44 7, 0 Negative Negative Negative
26 1, 3 7, 49 0, 13 Positive Negative Negative
27 31, 66 18, 58 12, 15 Negative Negative Negative
28 2, 29 15, 39 9, 13 Negative Negative Negative
29 1, 2 35, 51 13, 14 Positive Negative Negative
30 2, 31 44, 51 8, 16 Negative Negative Negative
31 5, 1 5, 4 8, 2 Positive Negative Negative
32 0, 2 44, 49 1, 7 Negative Negative Negative
33 11, 24 35, 37 3, 10 Negative Negative Negative
34 3, 1 2, 5 4, 8 Negative Negative Negative
35 2, 34 39, 56 1, 13 Negative Negative Negative
36 1, 2 18, 50 7, 11 Negative Negative Negative
37 24, 0 8, 51 3, 15 Positive Negative Negative
38 2, 3 35, 57 7, 8 Negative Negative Negative
39 29, 0 15, 0 10, 0 Negative Positive Negative
40 1, 2 8, 14 3, 7 Positive Positive Negative
41 3, 30 35, 53 11, 14 Positive Negative Negative
42 2, 30 44, 49 12, 13 Negative Negative Negative
43 1, 24 8, 14 1, 3 Positive Negative Negative
44 2, 31 15, 38 13, 16 Positive Negative Negative
45 26, 30 38, 58 11, 13 Negative Negative Negative
46 30, 68 14, 18 1, 3 Positive Positive Negative
47 3, 24 7, 8 13, 15 Positive Positive Negative
48 30, 33 14, 0 3, 15 Positive Positive Negative
49 2, 33 53, 0 3, 8 Negative Negative Negative
50 1, 30 8, 0 3, 13 Negative Negative Negative
51 2, 3 15, 35 3, 0 Positive Negative Negative
52 1, 23 15, 8 15, 0 Negative Negative Negative
53 2, 29 44, 50 7, 11 Negative Negative Negative
54 24, 0 40, 0 1, 3 Positive Negative Negative
55 2, 3 51, 57 1, 4 Positive Negative Negative
56 26, 68 27, 4 4, 13 Positive Negative Negative
57 11, 31 51, 56 1, 13 Positive Negative Negative
58 1, 2 8, 2 13, 0 Positive Negative Negative
59 1, 29 7, 44 1, 4 Negative Negative Negative
HLA, human leukocyte antigens; HCMV, cytomegalovirus; HHV-6, human herpesvirus-6; ACR, acute cellular rejection.
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Table 2 – Multivariate regression analysis and clinical variables using ACR as dependent variable.
Regression summary for dependent variable: ACR R (HLA DR × ACR), R = 0.39122164, R2 = 0.15305437, Adjusted R2 = –, F(13,45) = 0.62555
b* SE of b* b SE of b t(45) p-Value
Intercept 89.87960 34.51059 2.60441 0.012427
ICU donor −0.026915 0.156357 −0.00393 0.02286 −0.17214 0.864100
BDC donor 0.040342 0.154217 0.01144 0.04372 0.26159 0.794831
Gender donor 0.073123 0.154645 0.07156 0.15133 0.47284 0.638611
Age donor −0.133910 0.165004 −0.00487 0.00600 −0.81156 0.421319
BMI donor 0.089542 0.174625 0.01308 0.02551 0.51277 0.610622
Cold ischemia (min) 0.010176 0.149089 0.00002 0.00034 0.06825 0.945887
Warm ischemia (min) −0.195094 0.163400 −0.00396 0.00331 −1.19397 0.238747
HCMV DNA donor −0.133295 0.184690 −0.19933 0.27619 −0.72172 0.474198
HHV-6 DNA donor −0.019943 0.156192 −0.01929 0.15108 −0.12768 0.898969
HLA DR 15 donor 0.300259 0.168916 0.33345 0.18759 1.77756 0.082234
Ender recipient −0.075116 0.152701 −0.07774 0.15803 −0.49192 0.625171
Age recipient 0.199200 0.168171 0.00763 0.00644 1.18451 0.242431
BMI recipient 0.053993 0.156713 0.00602 0.01748 0.34453 0.732052
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cytomegalovirus; HHV-6, human herpesvirus-6; BMI, body mass inde
o have significant association. No association was found
etween CMV  DNA positivity in liver biopsies and HLA-DR15
resence.
Some studies have suggested that HLA compatibility can
ave clinical significance after liver transplantation.4,5 Manez
t al. suggest that an HLA-DR mismatch between donor
nd recipient increases the incidence of HCMV hepatitis and
nfections.4 Another study examined the incidence of HCMV
iremia after liver transplantation with the HLA matching
nfluence, and found no association.19
Some patients in this study developed graft rejection asso-
iated with HLA-DR15. An a recent study we showed that
1% of the recipients developed graft rejection.11 Acute or
hronic rejection remains the most common reason for graft
ailure, especially for patients who have HLA mismatching.6
he role of HLA matching between donor and recipient in
rgan transplant rejection has been pointed out in some stud-
es and a degree of HLA mismatching could be associated
ith increased graft failure.6,20 Menez et al. showed that HLA-
R mismatching may accelerate chronic rejection of liver
ransplants.4
In summary HHV-6 DNA was prevalent in liver donors stud-
ed as well as HLA-DR15. These findings suggest that detection
f HLA-DR15 in liver donor biopsies developed more  rejection
fter liver transplantation. However, further studies are neces-
ary to clarify these data, especially HHV-6 infection in donor
amples together with HLA mismatches.
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